FDA Expects Sharp Drop In Fee-Paying Drug Applications This Year
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
In what could be viewed as an ominous sign of declining pharmaceutical R&D productivity, FDA is predicting a sharp drop-off in fee-paying drug and biologic applications in the current fiscal year
You may also be interested in...
FDA Funding Bill In Senate Gives Generic Drugs More, But Commissioner Less
A Senate Appropriations Committee-approved funding package would provide the Center for Drug Evaluation and Research with $5 million more than requested by the Obama administration
FDA's NME Approval Rebound At Risk: Drought Of Novel Products In Line For Action In Remainder Of 2010 Could Depress Upward Trend From First Half
Almost one-third fewer novel product applications are on FDA’s user fee calendar for the second half of 2010 as compared to the docket at the same point in 2009, a dearth that could imperil the slow but steady improvement in annual new molecular entity and novel biologic approvals after the nadirs reached earlier in the decade.
Separate FDA Post-Market Drug Safety Office Outlined In Approps Bill Report
House subcommittee would provide FDA with $55 million more than the amount requested in President Obama's FY 2011 budget proposal.